R-HCVAD regimen

Jump to navigation Jump to search

WikiDoc Resources for R-HCVAD regimen

Articles

Most recent articles on R-HCVAD regimen

Most cited articles on R-HCVAD regimen

Review articles on R-HCVAD regimen

Articles on R-HCVAD regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on R-HCVAD regimen

Images of R-HCVAD regimen

Photos of R-HCVAD regimen

Podcasts & MP3s on R-HCVAD regimen

Videos on R-HCVAD regimen

Evidence Based Medicine

Cochrane Collaboration on R-HCVAD regimen

Bandolier on R-HCVAD regimen

TRIP on R-HCVAD regimen

Clinical Trials

Ongoing Trials on R-HCVAD regimen at Clinical Trials.gov

Trial results on R-HCVAD regimen

Clinical Trials on R-HCVAD regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on R-HCVAD regimen

NICE Guidance on R-HCVAD regimen

NHS PRODIGY Guidance

FDA on R-HCVAD regimen

CDC on R-HCVAD regimen

Books

Books on R-HCVAD regimen

News

R-HCVAD regimen in the news

Be alerted to news on R-HCVAD regimen

News trends on R-HCVAD regimen

Commentary

Blogs on R-HCVAD regimen

Definitions

Definitions of R-HCVAD regimen

Patient Resources / Community

Patient resources on R-HCVAD regimen

Discussion groups on R-HCVAD regimen

Patient Handouts on R-HCVAD regimen

Directions to Hospitals Treating R-HCVAD regimen

Risk calculators and risk factors for R-HCVAD regimen

Healthcare Provider Resources

Symptoms of R-HCVAD regimen

Causes & Risk Factors for R-HCVAD regimen

Diagnostic studies for R-HCVAD regimen

Treatment of R-HCVAD regimen

Continuing Medical Education (CME)

CME Programs on R-HCVAD regimen

International

R-HCVAD regimen en Espanol

R-HCVAD regimen en Francais

Business

R-HCVAD regimen in the Marketplace

Patents on R-HCVAD regimen

Experimental / Informatics

List of terms related to R-HCVAD regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Rituximab-Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen

Overview

R-HCVAD regimen refers to a regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of mantle cell lymphoma.[1]

Regimen

RRituximab

CCyclophosphamide

VVincristine (Oncovin)

ADoxorubicin (Adriamycin)

DDexamethasone

Indications

References

  1. 1.0 1.1 Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B; et al. (2005). "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine". J Clin Oncol. 23 (28): 7013–23. doi:10.1200/JCO.2005.01.1825. PMID 16145068.